Safe Use of Opioids in Chronic Kidney Disease and Hemodialysis Patients: Tips and Tricks for Non-Pain Specialists

References

• Hildebrandt F. Genetic kidney diseases. Lancet. 2010;375(9722):1287–1295. doi:10.1016/S0140-6736(10)60236-X
   PubMed Web of Science ®Google Scholar
• Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi:10.1016/S0140-6736(16)32064-5
   PubMed Web of Science ®Google Scholar
• Morton RL, Schlackow I, Mihaylova B, Staplin ND, Gray A, Cass A. The impact of social disadvantage in moderate-to-severe chronic kidney disease: an equity-focused systematic review. Nephrol Dial Transplant. 2016;31(1):46–56. doi:10.1093/ndt/gfu394
   PubMed Web of Science ®Google Scholar
• Cavalli A, Del Vecchio L, Locatelli F. Geriatric nephrology. J Nephrol. 2010;23(Suppl 15):S115.
   Google Scholar
• Innis J. Pain assessment and management for a dialysis patient with diabetic peripheral neuropathy. CANNT J. 2006;16(2):12–7, 20–6; quiz 18–9, 27–8.
   PubMedGoogle Scholar
• Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National kidney foundation hypertension and diabetes executive committees working group. Am J Kidney Dis. 2000;36(3):646–661. doi:10.1053/ajkd.2000.16225
   PubMed Web of Science ®Google Scholar
• Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014;27(2):188–204. doi:10.1111/sdi.12196
   PubMed Web of Science ®Google Scholar
• Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848–1853. doi:10.1136/heartjnl-2016-310794
   PubMed Web of Science ®Google Scholar
• Reis A, Luecke C, Davis TK, Kakajiwala A. Pain management in pediatric chronic kidney disease. J Pediatr Pharmacol Ther. 2018;23(3):192–202. doi:10.5863/1551-6776-23.3.192
   PubMedGoogle Scholar
• Schaefer F, Wingen AM, Hennicke M, Rigden S, Mehls O. Growth charts for prepubertal children with chronic renal failure due to congenital renal disorders. European study group for nutritional treatment of chronic renal failure in childhood. Pediatr Nephrol. 1996;10(3):288–293. doi:10.1007/BF00866762
   PubMed Web of Science ®Google Scholar
• Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol. 2012;27(3):363–373. doi:10.1007/s00467-011-1939-1
   PubMed Web of Science ®Google Scholar
• Xiao N, Jenkins TM, Nehus E, et al. Kidney function in severely obese adolescents undergoing bariatric surgery. Obesity. 2014;22(11):2319–2325. doi:10.1002/oby.20870
   PubMed Web of Science ®Google Scholar
• Ding W, Cheung WW, Mak RH. Impact of obesity on kidney function and blood pressure in children. World J Nephrol. 2015;4(2):223–229. doi:10.5527/wjn.v4.i2.223
   PubMedGoogle Scholar
• Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–1384. doi:10.1002/cncr.22904
   PubMed Web of Science ®Google Scholar
• Almutary H, Bonner A, Douglas C. Which patients with chronic kidney disease have the greatest symptom burden? A comparative study of advanced CKD stage and dialysis modality. J Ren Care. 2016;42(2):73–82. doi:10.1111/jorc.12152
   PubMed Web of Science ®Google Scholar
• Pham PC, Khaing K, Sievers TM, et al. 2017 update on pain management in patients with chronic kidney disease. Clin Kidney J. 2017;10(5):688–697. doi:10.1093/ckj/sfx080
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Addington-Hall JM, Edmonds PM, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med. 2007;10(6):1266. doi:10.1089/jpm.2007.0017
   PubMed Web of Science ®Google Scholar
• Murphy EL, Murtagh FE, Carey I, Sheerin NS. Understanding symptoms in patients with advanced chronic kidney disease managed without dialysis: use of a short patient-completed assessment tool. Nephron Clin Pract. 2009;111(1):c7480. doi:10.1159/000183177
   Google Scholar
• Noble H, Meyer PJ, Bridge DJ, Johnson DB, Kelly DD. Exploring symptoms in patients managed without dialysis: a qualitative research study. J Ren Care. 2010;36(1):9–15. doi:10.1111/j.1755-6686.2010.00140.x
   PubMedGoogle Scholar
• Selewski DT, Massengill SF, Troost JP, et al. Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a midwest pediatric nephrology consortium study. Pediatr Nephrol. 2014;29(12):2347–2356. doi:10.1007/s00467-014-2858-8
   PubMed Web of Science ®Google Scholar
• Douglas CA. Palliative care for patients with advance chronic kidney disease. J R Coll Physicians Edinb. 2014;44(3):224–231. doi:10.4997/JRCPE.2014.309
   PubMedGoogle Scholar
• Kramer A, Boenink R, Noordzij M, et al. The ERA-EDTA registry annual report 2017: a summary. Clin Kidney J. 2020. 1–17. doi:10.1093/ckj/sfaa048.
   Web of Science ®Google Scholar
• United States Renal Data System. 2019 USRDS annual data report: epidemiology of kidney disease in the United States. National institutes of health, national institute of diabetes and digestive and kidney diseases. Bethesda, MD; 2019. Available from: https://usrds.org/2019/view/USRDS_2019_ES_final.pdf. Accessed June 26, 2020.
   Google Scholar
• Calls J, Rodríguez Calero M, Hernández Sánchez D, et al. An evaluation of pain in haemodialysis patients using different validated measurement scales. Nefrologia. 2009;29(3):236–243. doi:10.3265/Nefrologia.2009.29.3.5120.en.full
   PubMed Web of Science ®Google Scholar
• Davison SN. Pain in haemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42(6):1239–1247. doi:10.1053/j.ajkd.2003.08.025
   PubMed Web of Science ®Google Scholar
• Brkovic T, Burilovic E, Puljak L. Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent haemodialysis: a systematic review. Patient Prefer Adherence. 2016;10:1131–1150. doi:10.2147/PPA.S103927
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007a;14(1):82–99. doi:10.1053/j.ackd.2006.10.001
   PubMed Web of Science ®Google Scholar
• Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504. doi:10.1016/j.jpainsymman.2004.02.021
   PubMed Web of Science ®Google Scholar
• Bailie GR, Mason NA, Bragg-Gresham JL, Gillespie BW, Young EW. Analgesic prescription patterns among haemodialysis patients in the DOPPS: potential for underprescription. Kidney Int. 2004;65(6):2419–2425. doi:10.1111/j.1523-1755.2004.00658.x
   PubMed Web of Science ®Google Scholar
• Coluzzi F. Assessing and treating chronic pain in patients with end-stage renal disease. Drugs. 2018;78(14):1459–1479. doi:10.1007/s40265-018-0980-9
   PubMed Web of Science ®Google Scholar
• Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166iv191. doi:10.1093/annonc/mdy152
   Web of Science ®Google Scholar
• Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and exogenous opioids in pain. Annu Rev Neurosci. 2018;8(41):453–473. doi:10.1146/annurev-neuro-080317-061522
   Web of Science ®Google Scholar
• Drewes AM, Jensen RD, Nielsen LM, et al. Differences between opioids: pharmacological, experimental, clinical and economical perspectives. Br J Clin Pharmacol. 2013;75(1):60–78. doi:10.1111/j.1365-2125.2012.04317.x
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV Jr, Breve F, Jr TR, Raffa RB, Strasburger SE, LeQuang JA. Considering tapentadol as a first-line analgesic: 14 questions. Pain Manag. 2017;Jul(4):331–339. doi:10.2217/pmt-2016-0063
   Google Scholar
• Raffa RB, Pergolizzi JV, Taylor R, Ossipov MH, NEMA Research Group. Nature’s first “atypical opioids”: kratom and mitragynines. J Clin Pharm Ther. 2018;43(3):437–441. doi:10.1111/jcpt.12676
   PubMed Web of Science ®Google Scholar
• Davis MP, Srivastava M. Demographics, assessment and management of pain in the elderly. Drugs Aging. 2003;20(1):23–57. doi:10.2165/00002512-200320010-00003
   PubMed Web of Science ®Google Scholar
• Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA. 2015;313:837–846. doi:10.1001/jama.2015.0602
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(suppl):1–150.
   Google Scholar
• Davison SN. Clinical pharmacology considerations in pain management in patients with advanced kidney failure. Clin J Am Soc Nephrol. 2019;14(6):917–931. doi:10.2215/CJN.05180418
   PubMed Web of Science ®Google Scholar
• Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the drug Bank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074D1082. doi:10.1093/nar/gkx1037
   Web of Science ®Google Scholar
• Way EL, Adler TK. The pharmacologic implications of the fate of morphine and its surrogates. Pharmacol Rev. 1960;12:383–446.
   PubMed Web of Science ®Google Scholar
• Kurella M, Bennett WM, Chertow GM. Analgesia in patients with ESRD: a review of available evidence. Am J Kidney Dis. 2003;42(2):217–228. doi:10.1016/S0272-6386(03)00645-0
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J. Pain Palliat Care Pharmacother. 2007b;21(2):5–16.
   PubMedGoogle Scholar
• Parmar MS, Parmar KS. Management of acute and post-operative pain in chronic kidney disease. Version 3. F1000Res. 2013;2:28. doi:10.12688/f1000research.2-28.v2
   PubMedGoogle Scholar
• Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther. 1988;43(1):63–71. doi:10.1038/clpt.1988.12
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Schmidt H, Tzvetkov M, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J. 2007;7(4):257–265. doi:10.1038/sj.tpj.6500406
   PubMed Web of Science ®Google Scholar
• Launay-Vacher V, Karie S, Fau JB, Izzedine H. Deray G treatment of pain in patients with renal insufficiency: the World Health Organization three-step ladder adapted. J Pain. 2005;6(3):137. doi:10.1016/j.jpain.2004.11.009
   PubMed Web of Science ®Google Scholar
• Murphy EJ. Acute pain management pharmacology for the patient with concurrent renal or hepatic disease. Anaesth Intensive Care. 2005;33(3):311–322. doi:10.1177/0310057X0503300306
   PubMed Web of Science ®Google Scholar
• King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European palliative care research collaborative opioid guidelines project. Palliat Med. 2011;25(5):525–552. doi:10.1177/0269216311406313
   PubMed Web of Science ®Google Scholar
• Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29(5 Suppl):S4756. doi:10.1016/j.jpainsymman.2005.01.010
   Web of Science ®Google Scholar
• Samolsky Dekel BG, Donati G, Vasarri A, et al. Dialyzability of oxycodone and its metabolites in chronic noncancer pain patients with end-stage renal disease. Pain Pract. 2017;17(5):604–615. doi:10.1111/papr.12483
   PubMed Web of Science ®Google Scholar
• Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth. 1996;8(1):13–18. doi:10.1016/0952-8180(95)00092-5
   PubMed Web of Science ®Google Scholar
• Fitzgerald J. Narcotic analgesics in renal failure. Conn Med. 1991;55(12):701–704.
   PubMedGoogle Scholar
• Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46(2):313–340. doi:10.2165/00003495-199346020-00008
   PubMed Web of Science ®Google Scholar
• Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med. 1996;101(1A):47S53S. doi:10.1016/S0002-9343(96)00138-6
   Google Scholar
• Izzedine H, Launay-Vacher V, Abbara C, Aymard G, Bassilios N, Deray G. Pharmacokinetics of tramadol in a haemodialysis patient. Nephron. 2002;92(3):755–756. doi:10.1159/000064092
   PubMed Web of Science ®Google Scholar
• Fainsinger R, Schoeller T, Boiskin M, Bruera E. Palliative care round: cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care. 1993;9(1):53–55. doi:10.1177/082585979300900110
   PubMedGoogle Scholar
• Babul N, Darke AC, Hagen N. Hydromorphone metabolite accumulation in renal failure. J Pain Symptom Manage. 1995;10(3):184–186. doi:10.1016/0885-3924(94)00121-Z
   PubMed Web of Science ®Google Scholar
• Davison SN, Mayo PR. Pain management in chronic kidney disease: the pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in haemodialysis patients. J Opioid Manag. 2008;4(6):335–6, 339–44.
   PubMedGoogle Scholar
• Lee MA, Leng ME, Tiernan EJ. Retrospective study of the use of hydromorphone in palliative care patients with normal and abnormal urea and creatinine. Palliat Med. 2001;15(1):26–34. doi:10.1191/026921601669626431
   PubMed Web of Science ®Google Scholar
• Paramanandam G, Prommer E, Schwenke DC. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med. 2011;14(9):1029–1033. doi:10.1089/jpm.2011.0103
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend. 1980;5(3):197–205. doi:10.1016/0376-8716(80)90180-5
   PubMed Web of Science ®Google Scholar
• Furlan V, Hafi A, Dessalles MC, Bouchez J, Charpentier B, Taburet AM. Methadone is poorly removed by haemodialysis. Nephrol Dial Transplant. 1999;14(1):254–255. doi:10.1093/ndt/14.1.254
   PubMed Web of Science ®Google Scholar
• Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5:2–19. doi:10.1016/j.jpain.2003.09.007
   PubMed Web of Science ®Google Scholar
• Koehntop DE, Rodman JH. Fentanyl pharmacokinetics in patients undergoing renal transplantation. Pharmacotherapy. 1997;17(4):746–752.
   PubMed Web of Science ®Google Scholar
• Bower S. Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure. J Pharm Pharmacol. 1982;34(2):102–106. doi:10.1111/j.2042-7158.1982.tb04194.x
   PubMed Web of Science ®Google Scholar
• Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet. 1996;31(6):410–422. doi:10.2165/00003088-199631060-00002
   PubMed Web of Science ®Google Scholar
• Mercadante S, Caligara M, Sapio M, Serretta R, Lodi F. Subcutaneous fentanyl infusion in a patient with bowel obstruction and renal failure. J Pain Symptom Manage. 1997;13(4):241–244. doi:10.1016/S0885-3924(97)00076-6
   PubMed Web of Science ®Google Scholar
• Bastani B, Jamal JA. Removal of morphine but not fentanyl during haemodialysis. Nephrol Dial Transplant. 1997;12(12):2802–2804. doi:10.1093/ndt/12.12.2802
   PubMed Web of Science ®Google Scholar
• Joh J, Sila MK, Bastani B. Nondialyzability of fentanyl with high-efficiency and high-flux membranes. Anesth Analg. 1998;86(2):447.
   PubMed Web of Science ®Google Scholar
• Han J, Saraf SL, Gordeuk VR. Gowhari M3. Safety of chronic transdermal fentanyl use in patients receiving haemodialysis. Am J Health Syst Pharm. 2016;73(13):947–948. doi:10.2146/ajhp150748
   PubMed Web of Science ®Google Scholar
• Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth. 1990;64(3):276–282. doi:10.1093/bja/64.3.276
   PubMed Web of Science ®Google Scholar
• Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent haemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain. 2006;10(8):743–748. doi:10.1016/j.ejpain.2005.12.001
   PubMed Web of Science ®Google Scholar
• Cone EJ, Gorodetzky CW, Yousefnejad D, Buchwald WF, Johnson RE. The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos. 1984;12(5):577–581.
   PubMed Web of Science ®Google Scholar
• Böger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med. 2006;20(Suppl 1):s1723.
   Google Scholar
• Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13(3):219–230. doi:10.1016/j.ejpain.2008.04.011
   PubMed Web of Science ®Google Scholar
• Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a next generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs of Today. 2009;45(7):483–496.
   PubMed Web of Science ®Google Scholar
• Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010;32(1):31–38. doi:10.1358/mf.2010.32.1.1434165
   PubMedGoogle Scholar
• Vadivelu N, Huang Y, Mirante B, et al. Patient considerations in the use of tapentadol for moderate to severe pain. Drug Healthc Patient Saf. 2013;5:151–159. doi:10.2147/DHPS.S28829
   PubMedGoogle Scholar
• Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: A randomized, double blind study. Curr Med Res Opin. 2009;25:1095–1104. doi:10.1185/03007990902816970
   PubMed Web of Science ®Google Scholar
• Butler AM, Kshirsagar AV, Brookhart MA. Opioid use in the US haemodialysis population. Am J Kidney Dis. 2014;63(1):171–173. doi:10.1053/j.ajkd.2013.09.008
   PubMed Web of Science ®Google Scholar
• Wyne A, Rai R, Cuerden M, Clark WF, Suri RS. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin J Am Soc Nephrol. 2011;6(2):326–333. doi:10.2215/CJN.04770610
   PubMed Web of Science ®Google Scholar
• Kimmel PL, Fwu CW, Abbott KC, Eggers AW, Kline PP, Eggers PW. Opioid prescription, morbidity, and mortality in united states dialysis patients. J Am Soc Nephrol. 2017;28(12):3658–3670. doi:10.1681/ASN.2017010098
   PubMed Web of Science ®Google Scholar
• Kern DM, Zhou S, Chavoshi S, et al. Treatment patterns, healthcare utilization, and costs of chronic opioid treatment for non-cancer pain in the United States. Am J Manag Care. 2015;21(3):e22234.
   Web of Science ®Google Scholar
• Eerdekens M, Beuter C, Lefeber C, van den Anker J. The challenge of developing pain medications for children: therapeutic needs and future perspectives. J Pain Res. 2019;23(12):1649–1664. doi:10.2147/JPR.S195788
   Web of Science ®Google Scholar
• Coluzzi F. “I am in pain”: is it really the magic formula to open the door of opioid abuse? Minerva Anestesiol. 2017;83(12):1332–1333. doi:10.23736/S0375-9393.17.12269-8
   PubMed Web of Science ®Google Scholar
• O’Brien T, Christrup LL, Drewes AM, et al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3–19. doi:10.1002/ejp.970
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Fornasari D, Pergolizzi J, Romualdi P. From acute to chronic pain: tapentadol in the progressive stages of this disease entity. Eur Rev Med Pharmacol Sci. 2017;21(7):1672–1683.
   PubMed Web of Science ®Google Scholar
• Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag. 2015;14(11):95–105. doi:10.2147/TCRM.S32193
   Web of Science ®Google Scholar
• Coluzzi F, Polati E, Freo U, Grilli M. Tapentadol: an effective option for the treatment of back pain. J Pain Res. 2019;16(12):1521–1528. doi:10.2147/JPR.S190176
   Web of Science ®Google Scholar
• Kress HG, Coluzzi F. Tapentadol in the management of cancer pain: current evidence and future perspectives. J Pain Res. 2019;16(12):1553–1560. doi:10.2147/JPR.S191543
   Web of Science ®Google Scholar
• Yamamoto S, Kazama JJ, Maruyama H, Nishi S, Narita I, Gejyo F. Patients undergoing dialysis therapy for 30 years or more survive with serious osteoarticular disorders. Clin Nephrol. 2008;70(6):496–502. doi:10.5414/CNP70496
   PubMed Web of Science ®Google Scholar
• Kessler M, Netter P, Azoulay E, Mayeux D, Pere P, Gaucher A. Dialysis-associated arthropathy: a multicentre survey of 171 patients receiving haemodialysis for over 10 years. The co-operative group on dialysis-associated arthropathy. Br J Rheumatol. 1992;31(3):157–162. doi:10.1093/rheumatology/31.3.157
   PubMedGoogle Scholar
• Lee DI, Andreoni CR, Rehman J, et al. Laparoscopic cyst decortication in autosomal dominant polycystic kidney disease: impact on pain, hypertension, and renal function. J Endourol. 2003;17(6):345–354. doi:10.1089/089277903767923100
   PubMed Web of Science ®Google Scholar
• Kumar S, Trivedi HL, Smith EK. Carpal tunnel syndrome: a complication of arteriovenous fistula in haemodialysis patients. Can Med Assoc J. 1975;113(1112):1070–1072.
   PubMedGoogle Scholar
• Liu JT, Su CH, Chen SY, Liew SJ, Chang CS. Spinal cord stimulation improves the microvascular perfusion insufficiency caused by critical limb ischemia. Neuromodulation. 2018;21(5):489–494. doi:10.1111/ner.12753
   PubMed Web of Science ®Google Scholar
• Aitken E, McLellan A, Glen J, Serpell M, Mactier R, Clancy M. Pain resulting from arteriovenous fistulae: prevalence and impact. Clin Nephrol. 2013;80(5):328–333. doi:10.5414/CN107917
   PubMed Web of Science ®Google Scholar
• Göksan B, Karaali-Savrun F, Ertan S, Savrun M. Haemodialysis-related headache. Cephalalgia. 2004;24(4):284–287. doi:10.1111/j.1468-2982.2004.00668.x
   PubMed Web of Science ®Google Scholar
• Ambrosio F, Finco G, Mattia C, et al. SIAARTI recommendations for chronic noncancer pain. Minerva Anestesiol. 2006;72(11):859–880.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Scerpa MS, Pergolizzi J. Naldemedine: a new option for OIBD. J Pain Res. 2020;13:1209–1222. doi:10.2147/JPR.S243435
   PubMed Web of Science ®Google Scholar
• Bui K, She F, Sostek M. The effects of renal impairment on the pharmacokinetics, safety, and tolerability of naloxegol. J Clin Pharmacol. 2014;54(12):1375–1382. doi:10.1002/jcph.349
   PubMed Web of Science ®Google Scholar
• Webster LR, Hale ME, Yamada T, Wild JE. A renal impairment subgroup analysis of the safety and efficacy of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain receiving opioid therapy. J Pain Res. 2020;13:605–612. doi:10.2147/JPR.S237833
   PubMed Web of Science ®Google Scholar
• Raffa RB, Taylor R Jr, Pergolizzi JV Jr. Treating opioid-induced constipation in patients taking other medications: avoiding CYP450 drug interactions. J Clin Pharm Ther. 2019;44(3):361–371. doi:10.1111/jcpt.12812
   PubMed Web of Science ®Google Scholar
• Ishida JH, McCulloch CE, Steinman MA, Grimes BA, Johansen KL. Opioid analgesics and adverse outcomes among hemodialysis patients. Clin J Am Soc Nephrol. 2018;13(5):746–753. doi:10.2215/CJN.09910917
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of “bone-impairing analgesics”: the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015;31(11):515–523. doi:10.2147/TCRM.S79409
   Web of Science ®Google Scholar
• Coluzzi F, Billeci D, Maggi M, Corona G. Testosterone deficiency in non-cancer opioid-treated patients. J Endocrinol Invest. 2018;41(12):1377–1388. doi:10.1007/s40618-018-0964-3
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Scerpa MS, Centanni M. The effect of opiates on bone formation and bone healing. Curr Osteoporos Rep. 2020;18:325–335. doi:10.1007/s11914-020-00585-4
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Bifulco F, Cuomo A, et al. The challenge of perioperative pain management in opioid-tolerant patients. Ther Clin Risk Manag. 2017;5(13):1163–1173. doi:10.2147/TCRM.S141332
   Web of Science ®Google Scholar
• Palmer S, Vecchio M, Craig JC, et al. Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. Kidney Int. 2013;84(1):179–191. doi:10.1038/ki.2013.77
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Lequang JA, Passik S, Coluzzi F. Using opioid therapy for pain in clinically challenging situations: questions for clinicians. Minerva Anestesiol. 2019;85(8):899–908. doi:10.23736/S0375-9393.19.13321-4
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Taylor R Jr, Pergolizzi JV Jr, Mattia C, Raffa RB. Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering). Braz J Anesthesiol. 2016;66(3):310–317. doi:10.1016/j.bjan.2016.02.008
   PubMedGoogle Scholar
• Triantafylidis LK, Hawley CE, Perry LP, Paik JM. The role of deprescribing in older adults with chronic kidney disease. Drugs Aging. 2018;35(11):973–984. doi:10.1007/s40266-018-0593-8
   PubMed Web of Science ®Google Scholar
• Marquito AB, Fernandes NM, Colugnati FA, de Paula RB. Identifying potential drug interactions in chronic kidney disease patients. J Bras Nefrol. 2014;36(1):26–34. doi:10.5935/0101-2800.20140006
   PubMedGoogle Scholar
• Raouf M, Bettinger J, Wegrzyn EW, Mathew RO, Fudin JJ. Pharmacotherapeutic management of neuropathic pain in end-stage renal disease. Kidney Dis. 2020;6(3):157–167. doi:10.1159/000504299
   Web of Science ®Google Scholar
• Takeshita J, Litzinger MH. Serotonin syndrome associated with tramadol. Prim Care Companion J Clin Psychiatry. 2009;11:273. doi:10.4088/PCC.08l00690
   PubMedGoogle Scholar
• Baldo BA, Rose MA. The anaesthetist, opioid analgesic drugs, and serotonin toxicity: a mechanistic and clinical review. Br J Anaesth. 2020;124(1):44–62. doi:10.1016/j.bja.2019.08.010
   PubMed Web of Science ®Google Scholar